electroCoreECOR
Market Cap: $38.3M
About: electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Employees: 62
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
6% more capital invested
Capital invested by funds: $6.25M [Q1] → $6.61M (+$358K) [Q2]
0% more funds holding
Funds holding: 22 [Q1] → 22 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.39% less ownership
Funds ownership: 16.88% [Q1] → 16.49% (-0.39%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for ECOR.